Oct. 30, 2025 -- Forward Therapeutics, Inc (“Forward”), a biotechnology company developing oral small molecule therapies for inflammation-driven diseases, today announced that the first participants have been dosed in its Phase 1 healthy volunteer trial evaluating FT2109, the company’s second TNF signaling inhibitor in development for chronic inflammatory diseases. FT2109 is a next-generation oral small molecule designed to inhibit TNFR1 signaling by binding to soluble TNF (sTNF), a primary dr

Oct. 28, 2025 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that negative symptom data for brilaroxazine from the Phase 3 RECOVER double-blind trial in patients with acute exacerbation of schizophrenia, and from the long-term open-label extension trial in

Oct. 30, 2025 -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. The global cancer-therapy landscape is undergoing a rapid evolution toward precision drug-delivery systems designed t

Gross proceeds from sales of shares amounting to $4.5 million and exercise of warrants providing a further $2.7 million Total gross inflow of cash of $14.7 million since the end of the second quarter 2025 Evaxion now has cash on hand to fund its operations and R&D programs into the second half of 2027 The exercises have reduced the number of outstanding warrants to purchase Evaxion American Depositary Shares (ADSs) by 1.0 million October 30, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clin

30, 2025 -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, today announced the presentation of new data on its first therapeutic candidate from its RedTail platform, CLD-401, at the Society of Immunotherapy for Cancer (SITC) Annual Meeting. CLD-401 is a tumor-tropic oncolytic virus designed to home to metastatic sites after systemic administra

KT-579 Phase 1 testing expected to begin in early 2026 Oct. 27, 2025 -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the presentation of new preclinical data for KT-579, its potent, selective, oral IRF5 degrader, demonstrating disease-modifying activity across multiple immuno-inflammatory diseases. The findings show that by selectively targeting an

October 28, 2025, Swarm Oncology Ltd. (“Swarm Oncology” or “Swarm”), a biotechnology company pioneering novel T cell therapies to achieve long-term remission in patients with advanced solid cancers, is pleased to announce a research collaboration with a leading US clinic to further broaden the feasibility and manufacturing of research-scale Swarm-T cell preparations by using samples from patients treated in the clinic’s cancer vaccine studies. This research collaboration further expands Swarm’s

Oct. 28, 2025 -- Causeway Therapeutics, a clinical-stage biotechnology company developing novel medicines for tendon disease, today announced positive topline data from its Phase 2 clinical trial evaluating TenoMiR® (CWT-001), a proprietary microRNA-29a (miR-29a) mimic, in patients with lateral epicondylitis (commonly known as tendinopathy of the elbow or tennis elbow). Whilst the full analysis population, which included patients who did not receive the investigational therapy at the site of te

Oct. 28, 2025 -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the first participant has been randomized in the company’s Phase 2 GALAXY trial. GALAXY is a global Phase 2 clinical trial designed to evaluate the efficacy and safety of xelafaslatide (formerly ONL1204) in patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD). X

IBSRELA patients reported treatment satisfaction in real-world survey Post-hoc analysis of T3MPO-1 and T3MPO-2 studies demonstrates effectiveness of IBSRELA in reducing abdominal bloating for patients with IBS-C Analysis of electronic health records suggests IBSRELA may reduce burden to healthcare system Oct. 28, 2025 -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet signifi